Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06582875
PHASE2

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Sponsor: University of Colorado, Denver

View on ClinicalTrials.gov

Summary

The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.

Official title: Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

126

Start Date

2025-03-06

Completion Date

2029-06-30

Last Updated

2025-05-06

Healthy Volunteers

No

Interventions

DRUG

Tirzepatide

Titrated to dose of 5 mg once weekly subcutaneous

OTHER

Placebo

Titrated to dose of 5 mg once weekly subcutaneous

Locations (1)

University of Colorado - Anschutz Medical Campus

Aurora, Colorado, United States